Mereo BioPharma Group Shares Outstanding History (MREO)
Mereo BioPharma Group reported 798.1M shares outstanding at the end of fiscal 2025.
View full Mereo BioPharma Group company overviewMereo BioPharma Group annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 798.1M | 3.1M | +0.39% |
| 2024 | 2024-12-31 | 795.0M | 93.7M | +13.36% |
| 2023 | 2023-12-31 | 701.3M | 76.4M | +12.22% |
| 2022 | 2022-12-31 | 624.9M | 40.0M | +6.84% |
| 2021 | 2021-12-31 | 584.9M | 246.0M | +72.56% |
| 2020 | 2020-12-31 | 339.0M | 241.0M | +246.01% |
| 2019 | 2019-12-31 | 98.0M | 26.7M | +37.51% |
| 2018 | 2018-12-31 | 71.2M | — | — |
Mereo BioPharma Group quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 798.5M | 3.0M | +0.37% |
| Q1 2026 | 2026-03-31 | 798.1M | 3.1M | +0.39% |
| Q4 2025 | 2025-12-31 | 798.1M | 3.1M | +0.39% |
| Q3 2025 | 2025-09-30 | 795.7M | 19.9M | +2.57% |
| Q2 2025 | 2025-06-30 | 795.5M | 26.2M | +3.41% |
| Q1 2025 | 2025-03-31 | 795.0M | 93.6M | +13.35% |
| Q4 2024 | 2024-12-31 | 795.0M | 93.7M | +13.36% |
| Q3 2024 | 2024-09-30 | 775.7M | — | — |
| Q2 2024 | 2024-06-30 | 769.3M | — | — |
| Q1 2024 | 2024-03-31 | 701.4M | — | — |
| Q4 2023 | 2023-12-31 | 701.3M | 0 | 0.00% |
| Q4 2022 | 2022-12-31 | 701.3M | — | — |
Mereo BioPharma Group shares outstanding trends
Over the last five fiscal years, Mereo BioPharma Group's shares outstanding moved from 339.0M to 798.1M, a change of 459.1M. The latest reported quarter, Q2 2026, shows 798.5M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mereo BioPharma Group source filings ↗